GlassScriptPhysician profile
Khine Swe Shan
NPI 1427587765
$2,400.12
in general payments reported to CMS, 2019-2025
22 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2022: $518 · 2023: $319 · 2024: $935 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.51 |
| Education | $255.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $343.65 | 2024-2025 | Rybrevant, Pipeline, Erleada |
| Seagen INC. | $272.97 | 2022-2023 | |
| Rigel Pharmaceuticals, INC. | $240.42 | 2022-2024 | Tavalisse, Rezlidhia |
| Caris Mpi, INC. | $221.22 | 2025 | Mi Cancer Seek |
| Genzyme Corporation | $169.92 | 2022-2023 | |
| Pfizer INC. | $144.59 | 2023-2024 | |
| Eisai INC. | $124.99 | 2024 | |
| Springworks Therapeutics, INC. | $122.55 | 2024 | Ogsiveo |
| Takeda Pharmaceuticals U.S.A., INC. | $112.29 | 2023-2025 | Alunbrig, Ninlaro |
| Lilly USA, LLC | $107.52 | 2024 | |
| Amarin Pharma, INC. | $105.00 | 2019 | |
| Incyte Corporation | $95.00 | 2022 | |
| Recordati_rare_diseases_inc. | $85.00 | 2024 | Sylvant |
| E.R. Squibb & Sons, L.L.C. | $57.20 | 2022-2025 | Opdivo |
| Teleflex LLC | $34.11 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $28.62 | 2025 | |
| Merck Sharp & Dohme LLC | $27.47 | 2025 | Keytruda, Keytruda Qlex |
| Sumitomo Pharma America, INC. | $25.12 | 2025 | Orgovyx |
| Daiichi Sankyo INC. | $24.65 | 2025 | Datroway |
| Exelixis INC. | $22.45 | 2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $19.75 | 2025 | Calquence |
| Beone Medicines USA, INC. | $15.63 | 2025 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khine Shan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.